Zobrazeno 1 - 10
of 76
pro vyhledávání: '"María San Román"'
Autor:
Víctor Albarrán, María San Román, Javier Pozas, Jesús Chamorro, Diana Isabel Rosero, Patricia Guerrero, Juan Carlos Calvo, Carlos González, Coral García de Quevedo, Patricia Pérez de Aguado, Jaime Moreno, Alfonso Cortés, Ainara Soria
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
Adoptive cell therapy (ACT) comprises different strategies to enhance the activity of T lymphocytes and other effector cells that orchestrate the antitumor immune response, including chimeric antigen receptor (CAR) T-cell therapy, T-cell receptor (TC
Externí odkaz:
https://doaj.org/article/dfa60e7ce0014d73a09aeca274ba7b8b
Autor:
María San-Román-Gil, Iñigo Martínez-Delfrade, Víctor Albarrán-Fernández, Patricia Guerrero-Serrano, Javier Pozas-Pérez, Jesús Chamorro-Pérez, Diana Rosero-Rodríguez, Pilar Sotoca-Rubio, Ana Maria Barrill-Corpa, Víctor Alia-Navarro, Carlos González-Merino, Coral García-de-Quevedo-Suero, Victoria López, Ignacio Ruz-Caracuel, Cristian Perna-Monroy, Reyes Ferreiro-Monteagudo
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
Immunotherapy has demonstrated a role in the therapeutic landscape of a small subset of patients with colorectal carcinoma (CRC) that harbor a microsatellite instability (MSI-H) status due to a deficient DNA mismatch repair (dMMR) system. The remarka
Externí odkaz:
https://doaj.org/article/764e50597193429a803f3c4afe79992e
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-12 (2022)
Abstract Background Lung cancer is the third most frequent tumor and the main cause of death by tumor in Spain. Although the incidence and mortality are still significantly higher in men than in women, the disparity between the sexes is decreasing. T
Externí odkaz:
https://doaj.org/article/831dc81ed95c40a4865a88194c51b27a
Autor:
Víctor Albarrán, Jesús Chamorro, Javier Pozas, María San Román, Diana Isabel Rosero, Cristina Saavedra, María Gion, Alfonso Cortés, Elena Escalera, Eva Guerra, Elena López Miranda, María Fernández Abad, Noelia Martínez Jañez
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
PARP inhibitors are progressively becoming a part of our therapeutic arsenal against BRCA-defective tumors, because of their capacity to induce synthetic lethality in cells with a deficiency in the homologous recombination repair system. Olaparib and
Externí odkaz:
https://doaj.org/article/e86c0ec339974c8c8252d1bb6e51b17f
Autor:
Pablo Alvarez-Ballesteros, Javier Buisan-Catevilla, Alvaro Beltrán-Corbellini, Iñigo Corral-Corral, Javier Pozas-Perez, Victor Albarran-Fernandez, Lucia Sanz-Gomez, Jorge Esteban-Villarrubia, Javier Torres-Jimenez, Jesús Chamorro-Perez, Diana Rosero-Rodriguez, María San Román-Gil, Ainara Soria-Rivas
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/f3e32b977b4644b4ad14b7be6c3b7c6e
Autor:
Figuerola-Tejerina, Angels, Rodríguez-Caravaca, Gil, Bustamante-Munguira, Juan, María San Román-Montero, Jesús, Durán-Poveda, Manuel
Publikováno v:
In Revista Española de Cardiología (English Edition) September 2016 69(9):842-848
Autor:
Figuerola-Tejerina, Angels, Rodríguez-Caravaca, Gil, Bustamante-Munguira, Juan, María San Román-Montero, Jesús, Durán-Poveda, Manuel
Publikováno v:
In Revista Española de Cardiología September 2016 69(9):842-848
Autor:
Víctor Albarrán, María Luisa Villamayor, Ignacio Ruz, Jesús Chamorro, Diana Isabel Rosero, Javier Pozas, María San Román, Pablo Álvarez Ballesteros, María Ángeles Vaz
Publikováno v:
Journal of Cancer Science and Clinical Therapeutics.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c5f966ff99b2516b1d714a747892b11b
https://doi.org/10.26502/jcsct.5079195
https://doi.org/10.26502/jcsct.5079195
Autor:
Víctor Albarrán, María Luisa Villamayor, Jesús Chamorro, Diana Isabel Rosero, Javier Pozas, María San Román, Juan Carlos Calvo, Patricia Pérez de Aguado, Jaime Moreno, Patricia Guerrero, Carlos González, Coral García de Quevedo, Pablo Álvarez-Ballesteros, María Ángeles Vaz
Publikováno v:
International journal of molecular sciences. 23(22)
Bone sarcomas are a heterogeneous group of rare tumors with a predominance in the young population. Few options of systemic treatment are available once they become unresectable and resistant to conventional chemotherapy. A better knowledge of the ke
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e0fb1e4e7a3297e3a847c2000c46a50c
https://pubmed.ncbi.nlm.nih.gov/36430263
https://pubmed.ncbi.nlm.nih.gov/36430263
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.